PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gupta, V.K.* ; Sahu, L.* ; Sonwal, S.* ; Suneetha, A.* ; Kim, D.H.* ; Kim, J.* ; Verma, H.K. ; Pavitra, E.* ; Raju, G.S.R.* ; Bhaskar, L.* ; Lee, H.U.* ; Huh, Y.S.*

Advances in biomedical applications of vitamin D for VDR targeted management of obesity and cancer.

BIOMED. PHARMACOTHER. 177:117001 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: 1,25(OH)2D3 is a fat-soluble vitamin, involved in regulating Ca2+ homeostasis in the body. Its storage in adipose tissue depends on the fat content of the body. Obesity is the result of abnormal lipid deposition due to the prolonged positive energy balance and increases the risk of several cancer types. Furthermore, it has been associated with vitamin D deficiency and defined as a low 25(OH)2D3 blood level. In addition, 1,25(OH)2D3 plays vital roles in Ca2+-Pi and glucose metabolism in the adipocytes of obese individuals and regulates the expressions of adipogenesis-associated genes in mature adipocytes. SCOPE AND APPROACH: The present contribution focused on the VDR mediated mechanisms interconnecting the obese condition and cancer proliferation due to 1,25(OH)2D3-deficiency in humans. This contribution also summarizes the identification and development of molecular targets for VDR-targeted drug discovery. KEY FINDINGS AND CONCLUSIONS: Several studies have revealed that cancer development in a background of 1,25(OH)2D3 deficient obesity involves the VDR gene. Moreover, 1,25(OH)2D3 is also known to influence several cellular processes, including differentiation, proliferation, and adhesion. The multifaceted physiology of obesity has improved our understanding of the cancer therapeutic targets. However, currently available anti-cancer drugs are notorious for their side effects, which have raised safety issues. Thus, there is interest in developing 1,25(OH)2D3-based therapies without any side effects.
Impact Factor
Scopus SNIP
Altmetric
6.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter 1,25(oh)(2)d(3) ; Cancer ; Carcinogenesis ; Obesity ; Vdr ; Vitamin D; Body-mass Index; Proliferator-activated Receptor; Dose-response Metaanalysis; Parathyroid-hormone Gene; D Signaling Pathways; Primary Liver-cancer; Breast-cancer; D Deficiency; 1-alpha,25-dihydroxyvitamin D-3; Colorectal-cancer
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1950-6007
e-ISSN 0753-3322
Zeitschrift Biomedicine & pharmacotherapy
Quellenangaben Band: 177, Heft: , Seiten: , Artikelnummer: 117001 Supplement: ,
Verlag Elsevier
Verlagsort Paris
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 80000 - German Center for Lung Research
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501810-007
Förderungen Korea Basic Science Institute research
Basic Science Research Program through the National Research Foundation of Korea (NRF) - Korean government (MSIT)
Korea Environmental Industry & Technology Institute (KEITI) - Ministry of Environment (MOE) of the Republic of Korea
DOI 10.1016/j.biopha.2024.117001
WOS ID 001261257900001
Scopus ID 85196794867
PubMed ID 38936194
Erfassungsdatum 2024-07-16
[➜Korrektur melden]